Zevra Therapeutics Announces Publication Of Arimoclomol In Infants With Niemann-Pick Disease Type C: Results From The Phase 2/3 Open-Label Pediatric Substudy In Molecular Genetics And Metabolism Reports

Loading news article.

Zevra Therapeutics Announces Publication Of Arimoclomol In Infants With Niemann-Pick Disease Type C: Results From The Phase 2/3 Open-Label Pediatric Substudy In Molecular Genetics And Metabolism Reports | WAPE

Zevra Therapeutics Announces Publication Of Arimoclomol In Infants With Niemann-Pick Disease Type C: Results From The Phase 2/3 Open-Label Pediatric Substudy In Molecular Genetics And Metabolism Reports

Article summary

Related companies

Comments —